SUMMARY

Injectable gold compounds have enjoyed widespread, but occasionally controversial, use in rheumatoid arthritis since the 1920s. This overview examines the data from controlled trials and longer-term observational studies. We conclude that gold is equivalent to other widely used second-line agents in terms of efficacy. Toxicity profiles are similar, apart from methotrexate. It is most efficacious and toxic in the first 2 yr of treatment. There appears to be a dose-response relationship for both efficacy and toxicity. Gold is one of the few agents that decreases the rate of progression of erosions (RR 0.38, 95 % CI 0.23-0.64). Gold compounds, therefore, have a definite place in the rheumatologist's armamentarium, but further research is required to determine optimal monitoring regimes as well as the role of maintenance therapy and combination therapy. KEY WORDS: Gold compounds, Injectable, Efficacy, Toxicity. INJECTABLE gold compounds have been used for the treatment of chronic arthritis since the early 1920s. Forestier [1] was one of a substantial number of early investigators who published virtually simultaneously on the therapeutic benefits of gold. He studied gold complexed with thiopropanolsulphonate (Allo-chrysine) in 550 subjects. He concluded that it wa